Monday, 5 June 2017

Global Nanoparticles Market Size, Share and Forecast upto 2024

Particles between 1 and 100 nanometers (nm) in size known as nanoparticles. An individual nanoparticle molecule behaves as a complete unit in terms of its property and transportation. Rapidly increasing public awareness for nanotechnology and introduction of new technologies will have many beneficial consequences. Moreover, increasing applications of nanotechnology in drug development and stringent guidelines for developing improved medical products are some of the prime factors which is expected to witness significant growth over the forecasted period. Furthermore, huge capital investment and high cost of nanoparticle analysis instrument is one of the key restraint for the growth of nanoparticle market. Due to its wide applications in healthcare, biomedical, electronics and among others the nanoparticle is currently a new area of research among many scientist. Rising government spending on pharmaceuticals and bio technology research and development and increasing focus on nanotechnology research also expected to experience significant growth. North America dominated the global nanoparticles market due to increasing chronic diseases such as diabetes, cardiovascular and cancer. Moreover, Europe is expected to witness the highest growth during the forecasted period, due to rapid research and development for nanoparticles. However, due to rampant economic growth of China and India, Asia Pacific is also expected to witness decent growth during the forecasted period. Furthermore, India is also an emerging hub for pharmaceuticals research and development.
Fill the form for an exclusive sample of Nanoparticles Market report @ https://www.coherentmarketinsights.com/insight/request-sample/216
Nanoparticles Market Taxonomy
On the basis of technology, the global market is classified into:
  • Liposomes
  • Nanotubes
  • Polymeric nanoparticles
  • Polymer conjugated drugs
  • Dendrimers
  • Inorganic nanoparticles
  • Others
On the basis of end user, the global market is classified into:
  • Pharmaceuticals industry
  • Biochemical industry
  • Research institutions
  • others
Nanoparticles Market Outlook – Surge in Drug Development in Pharmaceuticals Industry Augmenting Market Growth
Expansion of medical diagnostic industry and wide application of nanotechnology in healthcare sector such as neurology, cardiology and anti-infective is estimated to have a decent growth for nanoparticles market in the forecast period. Depending upon preparation methods nanoparticles, nanocapsules or nanospheres can be obtained. A long circulating particle made up of Biodegradable polymeric nanoparticles with hydrophilic polymer coating of poly ethylene glycol (PEG), used as a powerful drug delivery device. Due to its ability to deliver peptides, proteins and genes, it is also used as a DNA carrier in gene therapy. Numerous advantages for nanoparticles in drug delivery system is expected to Spector enormous growth during the forecasted period. Moreover, growing public awareness, improved technology and increase in chronic diseases escalate the global nanoparticles industry in North America. Emerging economy of Asia Pacific, such as China and India is expected to witness significant growth over the forecasted period.
Nanoparticles Market Challenges – Huge Capital Investment needed in Research and Development
Huge capital investment for research and development of new product and technology. Moreover, high cost of nanoparticles analysis instruments is expected to be one of the key restraints for global nanoparticles market.
Nanoparticles Market – Regulatory Scenario:
  • August, 2015, U.S. Food and Drug Administration (FDA), issued guidance to address various issues related to the use of nanotechnology in food ingredients intended for use in food for animals.
  • June, 2014, U.S. Food and Drug Administration (FDA), issued three guidelines related to the use of nanotechnology in regulated products, including cosmetics and food substances.
Some of the key players in the market includes Abraxis Biosciences, Inc., Novartis International AG, Gilead Sciences, Inc., Johnson & Johnson, Sigma-Tau Pharmaceuticals, Inc. Amgen, Inc., and Nano Interface Technology, Inc., Malvern Instruments Ltd., Horiba Ltd., Beckman Coulter, Shimadzu Corporation, Agilent Technology Inc, Hitachi Ltd., Wyatt Technology, among others.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1–206–701–6702

Posted by at No comments:
Labels: , , ,

Drug Eluting Stents Market Size, Share and Forecast upto 2024

High prevalence of artery disease along with the rise in geriatric population will drive growth of the overall drug eluting stents market
The rising old age population and the high occurrence of coronary artery diseases are some of the major factors which will propel the drug eluting stents market. Unhealthy dietary habits, sedentary lifestyles, and lack of proper exercise have resulted into the increased incidences of atherosclerosis. The demand for DES is rising significantly as atherosclerosis is extensively treated using DES. Additionally, constant decline in the price due to technological advancements along with increased adoption of DES across the globe is encouraging the acceptance of drug-eluting stent in the management of arterial diseases.
Fill the form for an exclusive sample of Drug Eluting Stents Market report @ https://www.coherentmarketinsights.com/insight/request-sample/207
In terms of geography, North America held the maximum share in the global drug eluting stent market. Scientific advancements such as the biodegradable stents have resulted in the dominance of the market in this region. However, Asia Pacific drug eluting stent market is likely to show a significant growth momentum in the near future. Markets in countries such as China and India are expected to record a considerable growth during the forecast period, owing to the increase in patient awareness associated with drug-eluting stents. Existence of large pool of old age population who are susceptible to arterial diseases and the increasing frequency of chronic diseases such as cardiac disorders and diabetes will drive the overall drug eluting stents market.
In the medical sector, a stent is a plastic or metal tube implanted into the lumen of a duct or anatomic vessel to keep the passage of blood vessels unobstructed. Stenting is the process of placement of a stent into the body. Various stents are used for a variety of purposes, from vascular and biliary stents, expandable coronary, relatively simple stents made of plastic, which are used to allow the uninterrupted flow of urine from the kidney to the bladder. A DES or drug-eluting stent is a coronary or peripheral stent or a scaffold that is usually placed into the tapering, diseased coronary or peripheral arteries that release a drug slowly to block cell proliferation. This process of stenting thwarts fibrosis that, along with clots or thrombi, could block the stented coronary artery, a process known as restenosis. Drug-eluting stents are usually placed within the coronary or peripheral artery by an interventional cardiologist or radiologist during an angioplasty process. Drug-eluting stents were approved by the FDA after the scientific trials showed that they were superior to the other metal stents for the management of coronary artery narrowing and they have lower rates of major cardiac events. The principle drug-eluting stents which were approved in the U.S. and Europe were covered with an mTOR inhibitor, or paclitaxel, such as sirolimus.
According to the data released by CDC in 2015, around 610,000 people die of coronary diseases in the U.S. every year, around 25% of the deaths caused by heart diseases. Also, CHD or coronary heart disease was the key disease killing over 370, 000 people per year. The statistics also said that every year around 735,000 people in the U.S. experience a heart attack. Of these 735,000 individuals, 525,000 were first heart attacks and the rest happened in patients who had already suffered from a heart attack. Rise in the number of heart disease along with diseases related to arterial narrowing such as renal artery stenosis will be responsible for a steady growth of the drug-eluting stent market.
Drug Eluting Stents Market Taxonomy
On the basis of type of product, the global market is classified into:
    • Polymer-free coatings
    • Polymer-based coatings
On the basis of application, the global market is classified into:
    • Peripheral Artery Disease
    • Coronary Artery Disease
The drug eluting stents market is highly fragmented, owing to the presence of many well established companies. The rivalry among these vendors is likely to increase with the rise in product diversifications, technological innovations, mergers and acquisitions, and with the introduction next-generation products. Some of the key players operating the global drug eluting stents industry are Biosensors International, Abbot Laboratories, Terumo, Boston Scientific, Medtronic and Lepu Medical. Some of the other important companies in the market are Biotronik, Envison Scientific, Stentys, MicroPosrt Medical, Meril Lifesciences, Shandong JW Medical Systems and Opto Circuits.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1–206–701–6702

Posted by at No comments:
Labels: , ,

Global Electronic Medical Records Market Insights, Opportunity Analysis, and Industry Forecast till 2024

Electronic Medical Records – Digital Transformation in Managing Patient’s Records
The global healthcare sector is undergoing a wave of transformation, with digitization being the core focus area of service providers. Healthcare IT products and systems are in high demand in emerging nations such as India, China, Brazil, Indonesia, and also Israel, as part of the ongoing upgrade of healthcare infrastructure in these countries. This is expected to propel growth of the electronic medical records market in these regions. Deployment of EMR systems involves long-term collaboration between the system developer and user. This service offering generates a continuous revenue model for electronic medical record service providers. The global market is therefore expected to grow at a sustainable rate over the foreseeable future.
The question for sustainability of this system arises on account of the existence of electronic health records (EHR), which allows easy access to patient health records irrespective of the time and physical location of the user. The EHR system, however, finds major applicability in large hospitals, and diagnostic centers thus paving the opportunity for EMR in smaller and medium-sized private clinics and health centers, which account for a major share of the healthcare practices.
Fill the form for an exclusive sample of Electronic Medical Records Market report @ https://www.coherentmarketinsights.com/insight/request-sample/196
The global electronic medical records market was valued at US$ 21,444.4 million in 2015 and is expected to witness a CAGR of 6.9% during the forecast period (2016 – 2024).
Figure 1. Global Electronic Medical Records Market Share, By Region (%)
Electronic Medical Records Market
Source: Coherent Market Insights Analysis (2017)
Ever-evolving patient needs ably met by easy to access EMR
Patients demand efficient healthcare service with access to proper medical records. Hospitals, clinics, diagnostic laboratories and ambulatory centers are constantly improving their healthcare infrastructure. Installation of electronic medical record system significantly reduces physician’s time and improves decision making. A digital mode of storing patient’s medical records allows the physician to revisit the patient’s medical history under his/her medical therapy and guidance. Increasing inclination of patients towards gaining easy access to their medical records through digital mode would propel implementation of electronic medical records. Moreover, this factor is also driving upgrade of the existing EMR systems making it more efficient and integrated to offer better patient care services. Catholic Health Services (CHS) and University of Maryland Medical System (UMMS) achieved Stage 6 recognition (almost fully automated/paperless medical records) by the Healthcare Information and Management Systems Society (HIMSS) Analytics in March 2017. Thus, demand for better technology-enabled care will drive growth of the electronic medical records market.
Inconsistent return on EMR systems hindering market growth
As age increases, risk for chronic diseases such as obesity, cardiovascular attack, neurological conditions, and cancer also increases. This in turn increases patient visits to specialty centers or hospitals equipped to treat and monitor such diseases. Thus, multiple doctor visits leads to uncertainty and redundant load on the electronic medical record system. Thus, healthcare facilities are facing challenges in quantifying monetary return on EMR systems. Moreover, competing priorities of healthcare facilities compromises on the use EMR system. Furthermore, affordability is a major challenge in emerging economies, deterring adoption and growth of electronic medical records market.
Get an exclusive discount on this report @ https://www.coherentmarketinsights.com/insight/request-discount/196
Digital transformation to underpin the adoption of EMR in emerging economies
Healthcare industry in emerging economies such as India, China, and Brazil is at the cusp of digital transformation. This could be the best opportunity for the electronic medical records market players to capitalize on the opportunity. Deployment of proper IT infrastructure coupled with personnel training would be required to support the growth of EMR market in these regions. As majority of population in Asia Pacific, Latin America and Africa belong to bottom of the pyramid, cost would be a major hindrance for growth of the EMR market. Local players are expected to gain ground by offering low cost products. Supportive regulations and favorable government incentives to implement EMR systems would be a major boosting factor for healthcare facilities in emerging economies.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1–206–701–6702

Posted by at No comments:
Labels: , ,

Ostomy Drainage Bags Market Size, Share and Forecast upto 2024

Growing geriatric population and increasing prevalence of ulcerative colitis creates large addressable market for ostomy drainage bags

In the recent past, prevalence of ulcerative colitis and IBD, especially among the geriatric population has increased significantly. Inflammatory bowel disease is common in developed countries, with higher prevalence in urban areas. Urbanization is a factor that might contribute to the increasing occurrence of the disease. However, with urbanization and rise in per capita income, the healthcare spends also increase proportionately. This will ensure timely and speedy recovery of the patients suffering from IBD and ulcerative colitis; thereby driving growth of the market.
North America held the largest share of the global ostomy drainage bags market, owing to high patient awareness and large geriatric population. However, Asia Pacific is projected to demonstrate high growth rates during the forecast period. India and China are projected to grow significantly in the global market for ostomy drainage bags in the Asia-Pacific region. Chief driving factors for the growth of industry in this region are increasing healthcare expenditure and presence of a large pool of patients.

Ostomy is a surgery to make an opening or stoma from a locale present in the interior of the body to the exterior. It predominantly treats diseases related to urinary or digestive systems. Ostomy may be permanent or temporary. In some cases an organ must be detached or removed, which is a permanent condition. However, when the organ or the specific part inside the body heals with time, and is not removed, the ostomy is temporary. The organ may be the colon, the small intestine, bladder or rectum. Whenever an ostomy is performed, wastes must be led outside the body through various procedures. This process of draining the wastes out of the body is known as ostomy drainage. The disposal bag used for this process is called ostomy drainage bag. After the ostomy procedure, bowel movements take place through the opening or stoma in the abdominal. This appliance has a bag and wafer. The wafer attaches to the abdominal wall with the help of an adhesive and the material is made of plastic. The primary function of the bag is to retrieve and retain the stool. Ostomy drainage bags are disposable and are replaced or emptied as required.

Fill the form for an exclusive sample of Ostomy Drainage Bags Market report @ https://www.coherentmarketinsights.com/insight/request-sample/186

According to National Institute of Diabetes and Digestive and Kidney Diseases, ostomy is broadly divided into three types - Ileostomy, Colostomy, and Urostomy. In Ileostomy, the base of the ileum or small intestine is attached to the opening or stoma. This goes around the anus, colon, and rectum. In colostomy, the colon is linked with the stoma, thereby bypassing the anus and rectum. In urostomy, the pipes that carry urine are linked to the stoma, which helps in bypassing the bladder.
Increasing awareness about ostomy procedure is one of the key factors that will propel the growth of the ostomy drainage bags market. Moreover, increasing incidence of Crohn’s disease and IBD (inflammatory bowel disease) would further propel growth of market in the foreseeable future.

Ostomy Drainage Bags Market Taxonomy

On the basis of product type, the global market is classified into:
Colostomy Bags
Urostomy Bags
Ileostomy Bags
On the basis of type of use, the global market is classified into:
Single-use Ostomy Drainage Bags
Multi-use Ostomy Drainage Bags Diagnostics

Due to factors such as increased awareness about colostomy, soaring incidence of colorectal cancer, and a variety of buying options for colostomy bags, the colostomy bags segment accounted for the largest share of the overall ostomy drainage bags market. According to American Cancer Society’s estimates, colorectal cancer is the third-most common cancer diagnosed in the U.S., with 95,520 new cases of colon cancer and 39,910 new cases of rectal cancer reported in the country in 2016. Increasing prevalence of colostomy and rectal cancer would necessitate ostomy, which in turn would drive overall growth of the ostomy drainage bags industry.

Request to view table of content @ https://www.coherentmarketinsights.com/ongoing-insight/toc/186

Some of the companies operating in the ostomy drainage bags market in the current scenario are Salts Healthcare Ltd., Welland Medical Ltd., Pelcin Healthcare Ltd., ConvaTec Inc., Hollister Incorporated, Coloplast A/S, Alcare Co Ltd, and B. Braun Melsungen AG.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1–206–701–6702
E-mail:sales@coherentmarketinsights.com
Website:https://www.coherentmarketinsights.com
Posted by at No comments:
Labels: , ,

Sunday, 4 June 2017

Sterility Testing Market Size, Share and Forecast upto 2024

Novel Technology in the pharmaceutical testing market is expected to favor the growth in sterility testing market:
Conventionally used microbiological testing methods for detection, enumeration, sterilization and identification tend to use culture methods majorly and were so often time consuming and labor-intensive. The drawback of such procedures in practical considerations often limits the extent to which microbiological tests applied regularly in both formulation development stage and for microbiological quality assurance. Furthermore, there are various well latest and upcoming methods such as MF sterility test apparatus from Merk Millipore, which is aseptically filter liquid samples for sterility testing apparatus used in sterility testing and may find wide application in the pharmaceutical sector. This is expected to be one of the important factors supporting growth of the sterility testing market. Rapid testing methods such as ATP bioluminescence, fluorescent labeling, nucleic acid probes and electrical resistance are commonly used in pharmaceutical testing. Obtaining perfect results by incorporating single method for all requirements is challenging, as products vary in their specifications, which is need to be adapted by the specific demands of the pharmaceutical and medical device situation. However, it is satisfactory to have the developments in ATP bioluminescence offering with increased sensitivity under adenylate kinase amplification potential specificity, phage lysis and internal calibration against the effects of excipients, laser scanning cytometry can be benefited through more specificity in proposed development using fluorescently labeled antibodies.
Major players in the sterility testing market are engaged in research and development process. For instance, bioMérieux SA – a biopharmaceutical company engaged in world class products for in-vitro testing – launched The BacT/ALERT 3D Dual-T apparatus for rapid and easy product control with non-destructive, dual-temperature microbial detection system.
Sterility testing in pharmaceutical manufacturing is a vital process during the sterilization and validation process along with release testing. It is an essential part of every sterilization validation process in several industries that makes it a vital procedure in manufacturing industry. It is an extremely difficult process that should be planned and executed with precision, which can be helpful in eliminating false positive results. Laboratory contamination or technician errors are the main causes of false positive results. Planned testing should be carried out in a clean room, where there is no or minimum chances of error are seen. This would also ensure compliance with U.S. Pharmacopeia (USP) requirements in terms of viable microbial air and surface counts. The unique requirements to employ sterility testing procedures as an official test and to determine the suitability are regulated under the good manufacturing practices guidelines.
An understanding of sterility testing benefits in validation process, designing is an important quality assurance issue is the need of providing an appropriate and authentic sterility test data. Furthermore, sterility testing is a tedious and artful process, which requires to be carried out by trained professionals. Also, investigation during the failure of sterility test, is a process that needs close look in environmental data along with other factors such as sample collection and sample procurement procedures. The rise in demand for sterilized products and their exclusivity in various industries is expected to fuel growth of the sterility testing market in the near future. The growth media utilized during the sterility testing must be properly prepared and tested to make the microbial growth adequately efficient. Increasing advancements in terms of sterility testing technologies is expected to support the sterility testing market growth over the forecast period (2016-2024). Various organizations are laying efforts in making the testing process more time efficient. For instance, Milliflex Rapid System, launched in 2010, for making the sterility testing procedure more time efficient without hindering the test result quality. The following decade is expected to provide major growth traction to players involved in the sterility testing market.
Fill the form for an exclusive sample of Sterility Testing Market report @ https://www.coherentmarketinsights.com/insight/request-sample/174
Sterility Testing Market Taxonomy:
By Product Type
  • Kits and Reagents
  • Instruments
  • Service
By Test Type
  • Membrane Filtration
  • Direct Inoculation
  • Container closure integrity testing
  • Antimicrobial effectiveness testing
  • Rapid micro test
    • ATP bioluminescence
    • Fluorescent labeling
    • Electrical resistance
By Application
  • Pharmaceutical and Biological Manufacturing
  • Medical Devices Manufacturing
  • Bioburden Test
  • Others Applications
Presence of major players in parenteral product manufacturing is projected to favor growth of the sterility testing market
The global sterility testing market is highly competitive and fragmented. Major players in the market are developing novel products through major spending on research and development to get a competitive edge over their counterparts. For instance, due to the strong product pipeline under market segment, Merck Millipore and bioMérieux are considered to be the toughest competitor in the market. Key players operating in the sterility testing market include Merck Millipore, Thermo Fisher Scientific, Inc., bioMérieux SA, SGS S.A., Sartorius AG, WuXi AppTec, and Charles River Laboratories International, Inc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1–206–701–6702

Posted by at No comments:
Labels: , ,

Saturday, 3 June 2017

Rheumatoid Arthritis Treatment Market - Size, Share and Forecast upto 2024

Plethora of research work to introduce effective treatment therapies in the global rheumatoid arthritis treatment market
Introduction of newer therapies are expected to fuel growth of rheumatoid arthritis treatment market in developed nations. Emerging economies are late adapters to new technologies and therapies, thus are potential markets for brands not yet marketed in these countries. The Chinese FDA recently approved Xeljanz for RZ treatment (2017). The product is awaiting approval from the EU. Among the Asian countries, India, China, Pakistan, and Bangladesh had major prevailing rheumatoid arthritis patients as per WHO–ILAR COPCORD (International League of Associations for Rheumatology) (Community Oriented Program for Control of Rheumatic Diseases) studies (2015). Some of the products in pipeline include:
  • Antibodies that target collagen II, an important protein in joint cartilage (Researchers at the Department of Immunology, Genetics and Pathology, Uppsala University, Sweden)
  • Stem cell I.V. therapy developed by Mesoblast Ltd. to treat RA patients unresponsive to TNF drugs (phase 2 trials)
More of such developments by the market players will be a significant contributor towards the growth of global rheumatoid arthritis treatment industry.
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the most. Treatments available for rheumatoid arthritis aids to relive symptoms and improve the joint function. A comprehensive treatment for RA usually involves integration of patient education, exercise, medications, and surgery (occasionally). The rheumatoid arthritis treatment market can be analyzed based on the drug type, as follows:
  • Biological drugs
    • Monoclonal antibodies
  • Non-Biologicals
    • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    • Corticosteroids
    • Analgesics
    • Disease-modifying anti-rheumatic drugs (DMARDs)
      • IL-6 inhibitors
      • TNF inhibitors
NSAIDs and corticosteroid are also the first-line fast acting therapeutic drugs. Acetylsalicylate, naproxen, ibuprofen, etodolac, and diclofenac are the NSAIDs usually prescribed as first-line drugs for RA. These drugs reduce inflammation, and pain. Corticosteroid medications are given either orally or parenterally to reduce inflammation and restore joint mobility and function. These class of drugs are more potent than NSAIDs and therefore usually preferred a first line therapy by prescribers. The global rheumatoid arthritis treatment industry is expected to be driven considerably in near future by DMARDs that form second line slow-acting therapeutic drugs. Longer therapeutic regimen with these drugs increases cost of therapy and also promote remission of joint destruction and deformity. Methotrexate is the most commonly prescribed second line drug for RA and hence, occupies major share in the respective segment of global rheumatoid arthritis treatment market. Tofacitinib (Xeljanz) is the most potential FDA approved Janus kinase (JAK) inhibitor available in the global market of rheumatoid arthritis treatment.
Fill the form for an exclusive sample of Rheumatoid Arthritis Treatment Market report @ https://www.coherentmarketinsights.com/insight/request-sample/166
FDA approved biologic drugs include rituximab (Rituxan, MabThera), abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel), certolizumab (Cimzia), anakinra (Kineret), infliximab (Remicade), golimumab (Simponi), and tocilizumab (Actemra). Besides these approved drugs, biosimilars in pipeline would fuel the rheumatoid arthritis treatment market growth in near future.
Key statistics pertaining to the global rheumatoid arthritis treatment market:
Over time, there is damage to cartilage and mobility function of the affected joint in rheumatoid arthritis patient.
  • Affects nearly 1.3 million U.S. population (RheumatoidArthritis.org)
  • Most common in the age group of 30-60 years
  • Global prevalence varies in the range of 0.3% to 1% (World Health Organization)
  • Average annual cost of treatment may go up to US $20,000 (RheumatoidArthritis.org)
  • According to the Arthritis Foundation, people with RA loose more workdays compared to those affected by any other medical condition
  • According to a Harvard University study published in the Journal of Global Health (2017), prevalence of rheumatoid arthritis in Southeast Asian countries was 0.4%, 0.42 in western Pacific region, and 0.37% in eastern Mediterranean countries
Some of the major players in the global rheumatoid arthritis treatment market are Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1–206–701–6702

Posted by at No comments:
Labels: , ,

Friday, 2 June 2017

Prefilled Syringes Market Size, Share and Forecast upto 2024

Rising demand for biologics and self-injection products to augment market growth
A large number of newly approved biologics and drugs demand for PFS delivery devices for the subcutaneous (SC) self-injection of biopharmaceuticals. Also, the need for simpler self-injection procedures and improved patient compliance for auto injectors, large-volume patch injectors and pens is on the rise. This in turn is expected to favor growth of the prefilled syringes market over the forecast period (2016–2024). Patient exposure towards the routine injection can affect patient compliance, as it can cause significant discomfort to the user. Introduction of large volume biologics though, have helped rise in adoption rate of prefilled syringes. This in turn is expected to favor the market over the forecast period. Some factors such as growth in adoption of injectable drugs, success and growth of biologics, increased global vaccination, increased drug self-administration trend, technological advancements in the manufacture of PFS, and development of advanced PFS would further augment market growth.
Rise in number of applications is to favor the expansion of global prefilled syringes market:
Prefilled syringes market is expanding rapidly globally due to its various applications in overall healthcare sector. Nowadays, PFS manufacturing companies are focused on promoting use of the product in various application especially in homecare settings, which further is projected to favor increase in customer base in various regions. Furthermore, manufacturers are working towards developing PFS vaccines to help in indications such as various infectious disease and cancer. PFS are also being efficiently used in emergency medical services and in emergency section of hospitals. According to Frederick Furness Publishing Ltd, around 70% of atropine syringes prepared by the hospital staff are pre-filled and can be immediately used in emergency conditions.
Fill the form for an exclusive sample of Prefilled Syringes Market report @ https://www.coherentmarketinsights.com/insight/request-sample/162
Highly consolidated market is expected to favor the sales revenue of prefilled syringes market:
There are around 20 pharmaceutical companies that are involved in manufacturing and marketing of prefilled syringes as preferred delivery device of around 50 injectable drugs and vaccines, which contributes significantly to the sales revenue of these players. Furthermore, there are few recent acquisitions by the big brands in market of prefilled syringes such as in 2012, Becton Dickinson and Company acquired Safety Syringes, Inc., which is further expected to favor the company’s syringes manufacturing efficiency and increase its product portfolio.
Parenteral drugs are the second most preferred type of drugs after oral solid dosage forms and also holds second largest market share in terms of revenue in overall pharmaceutical market. Various benefits such as ease in administration, better patient compliance and 100% bioavailability are the few important factors that are expected to favor growth of the prefilled syringes market over the forecast period (2016–2024). Prefilled syringes segment is the one of the most important of the parenteral products market. However, volume sales in the market is rather low as it is a fairly novel product. The market is expected to gain traction over the forecast period, with increasing number of products and growing awareness among the populace about the benefits of the product. There are various factors such as ease in administration and minimum contact with the exposed environment that are expected to favor growth of the prefilled syringes market in the near future. Use of syringes with prefilled drugs would be especially useful in emergency situations. According to Drug Development & Delivery, around 3.5 billion of prefilled syringes are produced each year and the existing numbers are expected to grow by the rate of around 9.0 – 10% annually.
Prefilled Syringes market taxonomy:
By Application
  • Monoclonal Antibodies
  • Vaccines
  • Others
By Material Type
  • Polymer
  • PVC
  • Cyclo-olefin Polymer(COP)
  • Glass
By Design
  • Single Chambered
  • Dual Chambered
  • Multi-Chambered
Key players operating in the prefilled syringes market include Becton Dickinson & Co., Gerresheimer, Medtronic, Baxter International, SCHOTT AG, West Pharmaceuticals, Vetter International, Unilife Corporation, Stevanato Group, and Terumo Corporation
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1–206–701–6702

Posted by at No comments:
Labels: , ,
Subscribe to: Posts (Atom)